These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Common genetic variations of the renin-angiotensin-aldosterone system and response to acute angiotensin I-converting enzyme inhibition in essential hypertension. Hannila-Handelberg T; Kontula KK; Paukku K; Lehtonen JY; Virtamo J; Tikkanen I; Hiltunen TP J Hypertens; 2010 Apr; 28(4):771-9. PubMed ID: 20027122 [TBL] [Abstract][Full Text] [Related]
26. Establishing correlation between genetics and nonresponse. Raina SK J Postgrad Med; 2015; 61(2):148. PubMed ID: 25766362 [No Abstract] [Full Text] [Related]
27. Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies. Lanzani C; Citterio L; Glorioso N; Manunta P; Tripodi G; Salvi E; Carpini SD; Ferrandi M; Messaggio E; Staessen JA; Cusi D; Macciardi F; Argiolas G; Valentini G; Ferrari P; Bianchi G Sci Transl Med; 2010 Nov; 2(59):59ra87. PubMed ID: 21106941 [TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms related to the renin-angiotensin-aldosterone system and response to antihypertensive drugs. Taverne K; de Groot M; de Boer A; Klungel O Expert Opin Drug Metab Toxicol; 2010 Apr; 6(4):439-60. PubMed ID: 20102285 [TBL] [Abstract][Full Text] [Related]
29. Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Turner ST; Chapman AB; Schwartz GL; Boerwinkle E Am J Hypertens; 2003 Oct; 16(10):834-9. PubMed ID: 14553962 [TBL] [Abstract][Full Text] [Related]
30. Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers. Höcht C; Bertera FM; Mayer MA; Taira CA Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):199-211. PubMed ID: 20095790 [TBL] [Abstract][Full Text] [Related]
31. Interactions between five candidate genes and antihypertensive drug therapy on blood pressure. Schelleman H; Stricker BH; Verschuren WM; de Boer A; Kroon AA; de Leeuw PW; Kromhout D; Klungel OH Pharmacogenomics J; 2006; 6(1):22-6. PubMed ID: 16314886 [TBL] [Abstract][Full Text] [Related]
32. Genetic mapping and tailored antihypertensive therapy. Ferrari P; Bianchi G Cardiovasc Drugs Ther; 2000 Aug; 14(4):387-95. PubMed ID: 10999645 [TBL] [Abstract][Full Text] [Related]
33. Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations. Baudin B Pharmacogenomics; 2002 Jan; 3(1):65-73. PubMed ID: 11966404 [TBL] [Abstract][Full Text] [Related]
35. Pharmacogenomics: a new approach to individual therapy of hypertension? Ferrari P Curr Opin Nephrol Hypertens; 1998 Mar; 7(2):217-22. PubMed ID: 9529626 [TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Arnett DK; Davis BR; Ford CE; Boerwinkle E; Leiendecker-Foster C; Miller MB; Black H; Eckfeldt JH Circulation; 2005 Jun; 111(25):3374-83. PubMed ID: 15967849 [TBL] [Abstract][Full Text] [Related]
39. Current concepts and molecular mechanisms in pharmacogenetics of essential hypertension. Rahman F; Muthaiah N; Kumaramanickavel G Indian J Pharmacol; 2021; 53(4):301-309. PubMed ID: 34414909 [TBL] [Abstract][Full Text] [Related]
40. Trends in pharmacogenomics of drugs acting on hypertension. Trotta R; Donati MB; Iacoviello L Pharmacol Res; 2004 Apr; 49(4):351-6. PubMed ID: 15202514 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]